Research advances in nanomedicine applied to the systemic treatment of colorectal cancer
L Yin, H Li, L Shi, K Chen, H Pan… - International Journal of …, 2023 - Wiley Online Library
The systematic treatment of colorectal cancer (CRC) still has room for improvement. The
efficacy of chemotherapy, that of anti‐vascular therapy, and that of immunotherapy have …
efficacy of chemotherapy, that of anti‐vascular therapy, and that of immunotherapy have …
Targeting key RNA methylation enzymes to improve the outcome of colorectal cancer chemotherapy
C Shao, Y Han, Y Huang, Z Zhang… - International …, 2023 - spandidos-publications.com
RNA methylation modifications are closely linked to tumor development, migration, invasion
and responses to various therapies. Recent studies have shown notable advancements …
and responses to various therapies. Recent studies have shown notable advancements …
Increasing burden of colorectal cancer in China
R Qu, Y Ma, Z Zhang, W Fu - The Lancet Gastroenterology & …, 2022 - thelancet.com
The burden of colorectal cancer is on the rise globally due to increasing prevalence.
According to the Article by the Global Burden of Disease (GBD) 2019 Colorectal Cancer …
According to the Article by the Global Burden of Disease (GBD) 2019 Colorectal Cancer …
Use of cidofovir in recent outbreak of adenovirus-associated acute liver failure in children
A Verma, S Vimalesvaran, T Lampejo… - The Lancet …, 2022 - thelancet.com
The burden of colorectal cancer is on the rise globally due to increasing prevalence.
According to the Article by the Global Burden of Disease (GBD) 2019 Colorectal Cancer …
According to the Article by the Global Burden of Disease (GBD) 2019 Colorectal Cancer …
Clinical characteristics and survival analysis of colorectal cancer in China: a retrospective cohort study with 13,328 patients from southern China
L Fang, Z Yang, M Zhang, M Meng, J Feng… - Gastroenterology …, 2021 - academic.oup.com
Background Colorectal cancer (CRC) is one of the most common cancers in China.
However, detailed clinical characteristics and survival information are limited. This study …
However, detailed clinical characteristics and survival information are limited. This study …
Locally advanced rectal cancer with dMMR/MSI-H may be excused from surgery after neoadjuvant anti-PD-1 monotherapy: a multiple-center, cohort study
R Yang, T Wu, J Yu, X Cai, G Li, X Li, W Huang… - Frontiers in …, 2023 - frontiersin.org
Objective Examine patients with locally advanced rectal cancer (LARC) with deficient
mismatch repair (dMMR) or microsatellite instability-high (MSI-H) who received neoadjuvant …
mismatch repair (dMMR) or microsatellite instability-high (MSI-H) who received neoadjuvant …
Real-world outcomes of regorafenib combined with immune checkpoint inhibitors in patients with advanced or metastatic microsatellite stable colorectal cancer: A …
K Yang, L Han, S Wu, X Qu, Q Li, C Zhao… - Cancer Immunology …, 2022 - Springer
Background Treatment strategies are limited for patients with chemotherapy refractory
microsatellite stable (MSS) colorectal cancer. We aim to evaluate the efficacy and safety of …
microsatellite stable (MSS) colorectal cancer. We aim to evaluate the efficacy and safety of …
The IGF2BP3–COPS7B Axis Facilitates mRNA Translation to Drive Colorectal Cancer Progression
J Tang, S Wang, M Weng, Q Guo, L Ren, Y He, Z Cui… - Cancer Research, 2023 - AACR
Many studies have provided valuable information about genomic and transcriptomic
changes that occur in colorectal cancer. However, protein abundance cannot be reliably …
changes that occur in colorectal cancer. However, protein abundance cannot be reliably …
Multi-perspective comparison of the immune microenvironment of primary colorectal cancer and liver metastases
Y He, Y Han, A Fan, D Li, B Wang, K Ji, X Wang… - Journal of Translational …, 2022 - Springer
Background Liver metastases are a major contributor to the poor immunotherapy response
in colorectal cancer patients. However, the distinctions in the immune microenvironment …
in colorectal cancer patients. However, the distinctions in the immune microenvironment …
[HTML][HTML] Comparative study of radiomics, tumor morphology, and clinicopathological factors in predicting overall survival of patients with rectal cancer before surgery
Z Chuanji, W Zheng, L Shaolv, M Linghou, L Yixin… - Translational …, 2022 - Elsevier
We compared the ability of a radiomics model, morphological imaging model, and
clinicopathological risk model to predict 3-year overall survival (OS) in 206 patients with …
clinicopathological risk model to predict 3-year overall survival (OS) in 206 patients with …